Genetic polymorphisms and the risk of progressive renal failure in elderly Hungarian patients

Hemodialysis International

Volumn 15, Issue 4, 2011, Pages 501-508

  Zsom, Marianna ^a,b   Fülöp, Tibor ^c   Zsom, Lajos ^c   Baráth, Ákos ^d   Maróti, Zoltán ^d   Endreffy, Emoke ^d  

^a Department of Ophthalmology of Szent Rókus Hospital   (Hungary)

^b Principal SMO Kft   (Hungary)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Chronic kidney disease; End stage renal disease; Endothelin; Endothelium; Genetic polymorphisms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ARYLDIALKYLPHOSPHATASE 1; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; GEL ELECTROPHORESIS; GENE AMPLIFICATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GLOMERULONEPHRITIS; HUMAN; HUNGARY; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MELTING POINT; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; ARYLDIALKYLPHOSPHATASE; ENDOTHELIN-1; FEMALE; HUMANS; HUNGARY; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RISK FACTORS;

EID: 80054897628     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00593.x     Document Type: Article

References (39)

1. Diaz-Buxo JA, Woods HF. Protecting the endothelium: A new focus for management of chronic kidney disease. Hemodial Int. 2006; 10:42-48.
2. Cattell V. The nitric oxide pathway in glomerulonephritis. Curr Opin Nephrol Hypertens. 1995; 4:359-364.
3. Nakayama M, Yasue H, Yoshimura M, etal. T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999; 99:2864-2870.
4. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. 2000; 57:405-413.
5. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003; 108:2184-2190.
6. Sorokin A, Kohan D. Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol. 2003; 285:F579-F589.
7. Ruíz-Ortega M, Gomez-Garre D, Alcazar R, etal. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens Suppl. 1994; 12:S51-S58.
8. Tiret L, Poirier O, Hallet V, etal. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension. 1999; 33:1169-1174.
9. Tanaka C, Kamide K, Takiuchi S, Kawano Y, Miyata T. Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene. Hypertens Res. 2004; 27:367-371.
10. Vianna AC, Mocelin AJ, Matsuo T, etal. Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int. 2007; 11:210-216.
11. Frosst P, Blom HJ, Milos R, etal. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10:111-113.
12. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: Clinical consequences. Am J Pharmacogenomics. 2001; 1:189-201.
13. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int. 2008; 12:471-479.
14. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998; 423:57-60.
15. Schunkert H, Hense HW, Gimenez-Roqueplo AP, etal. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension. 1997; 29:628-633.
16. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest. 1995; 95:948-953.
17. Gumprecht J, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E. Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: Risk of chronic renal failure. End-Stage Renal Disease Study Group. Kidney Int. 2000; 58:513-519.
18. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int. 1999; 56:2173-2180.
19. Aslanidis C, Nauck M, Schmitz G. High-speed prothrombin G-->A 20210 and methylenetetrahydrofolate reductase C-->T 677 mutation detection using real-time fluorescence PCR and melting curves. Biotechniques. 1999; 27:234-236.
20. Pocsai Z, Toth Z, Paragh G, Szeles G, Adany R. Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real time PCR technology. Clin Chim Acta. 2003; 332:31-36.
21. Chuang LM, Chiu KC, Chiang FT, etal. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with hypertension, non-insulin-dependent diabetes mellitus, and coronary heart disease in Taiwan. Metabolism. 1997; 46:1211-1214.
22. Malin R, Wirta V, Hiltunen TP, Lehtimaki T. Rapid detection of angiotensinogen M/T235 polymorphism by fluorescence probe melting curves. Clin Chem. 2000; 46:880-881.
23. Haszon I, Friedman AL, Papp F, etal. ACE gene polymorphism and renal scarring in primary vesicoureteric reflux. Pediatr Nephrol. 2002; 17:1027-1031.
24. Asakimori Y, Yorioka N, Taniguchi Y, etal. T(-786)-->C polymorphism of the endothelial nitric oxide synthase gene influences the progression of renal disease. Nephron. 2002; 91:747-751.
25. Noiri E, Taguchi J, Nakao A, Fujita T. MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care. 2000; 23:260.
26. Makita Y, Moczulski DK, Bochenski J, Smiles AM, Warram JH, Krolewski AS. Methylenetetrahydrofolate reductase gene polymorphism and susceptibility to diabetic nephropathy in type 1 diabetes. Am J Kidney Dis. 2003; 41:1189-1194.
27. Koupepidou P, Deltas C, Christofides TC, Athanasiou Y, Zouvani I, Pierides A. The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol. 2005; 24:287-294.
28. Schiavon R, Battaglia P, De Fanti E, etal. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: Comparison with the PON1 allele polymorphism. Clin Chim Acta. 2002; 324:39-44.
29. Zhang B, Eto S, Fan P, etal. Paraoxonase (Pon1) Q192R polymorphism and serum Pon1 activity in diabetic patients on maintenance hemodialysis. Clin Nephrol. 2003; 60:257-265.
30. Reiterová J, Merta M, Stekrova J, etal. Influence of endothelin-1 gene polymorphisms on the progression of autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2006; 29:182-188.
31. Jardine A, Padmanabhan N, Connell JM. Angiotensin converting enzyme gene polymorphisms and renal disease. Curr Opin Nephrol Hypertens. 1998; 7:259-264.
32. Hsieh MC, Lin SR, Hsieh TJ, etal. Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. Nephrol Dial Transplant. 2000; 15:1008-1013.
33. Park H, Choi S, Kim B, etal. Polymorphism of the ACE gene in dialysis patients: Overexpression of DD genotype in type 2 diabetic end-stage renal failure patients. Yonsei Med J. 2005; 46:779-787.
34. Palomo-Pinon S, Gutierrez-Rodriguez ME, Diaz-Flores M, etal. DD genotype of angiotensin-converting enzyme in type 2 diabetes mellitus with renal disease in Mexican Mestizos. Nephrology. 2009; 14:235-239.
35. Fabris B, Bortoletto M, Candido R, etal. Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension. J Hypertens. 2005; 23:309-316.
36. McLaughlin KJ, Harden PN, Ueda S, Boulton-Jones JM, Connell JM, Jardine AG. The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases. Hypertension. 1996; 28:912-915.
37. Parsa A, Lovett D, Peden E, Zhu L, Seldin M, Criswell L. Renin-angiotensin system gene polymorphisms predict the progression to renal insufficiency among Asians with lupus nephritis. Genes Immun. 2005; 6:217-224.
38. van den Born B-JH, van Montfrans GA, Uitterlinden AG, Zwinderman AH, Koopmans RP. The M235T polymorphism in the angiotensinogen gene is associated with the risk of malignant hypertension in white patients. J Hypertens. 2007; 25:2227-2233.
39. Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A. Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant. 2006; 21:979-983.